Trastuzumab Deruxtecan, and pembrolizumab in participants with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
DS8201-A-U106
Phase 1 other active
Quick answer
Trastuzumab Deruxtecan, and pembrolizumab in participants with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer for Locally advanced/metastatic breast or non-small cell lung cancer is a Phase 1 program (other) at Daiichi Sankyo Europe GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Daiichi Sankyo Europe GmbH
- Indication
- Locally advanced/metastatic breast or non-small cell lung cancer
- Phase
- Phase 1
- Modality
- other
- Status
- active